Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Med Sci. 2014 Feb 24;10(1):149-53. doi: 10.5114/aoms.2013.36927. Epub 2013 Aug 12.

Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer.

Author information

  • 1Department of General Surgery, Zhongshan Hospital, Research Institute of Digestive Diseases, Xiamen University, Xiamen, Fujian Province, China.
  • 2Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University, Shanghai, China.

Abstract

INTRODUCTIONS:

Phospho-PRAS40(Thr246) (phosphorylated proline-rich Akt substrate of 40 kilodaltons at Thr246) is a biomarker for phosphatidylinositol 3-kinase (PI3K) pathway activation and AKT inhibitors sensitivity.

MATERIAL AND METHODS:

In this study, we immunohistochemically investigated the expression of phospho-PRAS40(Thr246) in 141 gastric cancer tumors, and evaluated its clinicopathological and prognostic significance.

RESULTS:

Sixty-four cases (45.4%) were defined as phospho-PRAS40(Thr246) positive. Phospho-PRAS40(Thr246) correlated positively with lymph node metastasis, lymphatic infiltration, vascular infiltration and shorter survival. Furthermore, phospho-PRAS40(Thr246) is an independent prognostic factor for gastric cancer.

CONCLUSIONS:

Our data suggest that phospho-PRAS40(Thr246) was frequently expressed in gastric cancers, and correlated with malignant progression and poor prognosis of patients. PI3K pathway-targeted therapies should be considered in the future treatment of gastric cancers.

KEYWORDS:

PI3K; PRAS40; phosphorylation; prognosis; targeted therapy

PMID:
24701227
[PubMed]
PMCID:
PMC3953967
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk